Hans Clevers, now the Head of pharma Research and Early Development (pRED) at Roche, Basel, was formerly a renowned group leader at the Hubrecht Institute. His Organoid group, previously known as Clevers group, has been instrumental in advancing our understanding of tissue development and cancer using organoids derived from adult Lgr5 stem cells. His pioneering work in this field includes identifying TCF as a key effector in the Wnt pathway and exploring its role in organoid development and cancer initiation, particularly in colon carcinoma cells with APC deficiency.